Did you see this data Paolo A. Ascierto presents @BMS Realtivity048 ASCO PD-1/LAG3/CTLA4 with OS curve !! Once again melanoma pushes the boundaries.... currently accruing this regimen +/-sarilumab #ASCO24 The Angeles Clinic NYU Langone Health MassGeneral Medicine Dana-Farber ascopubs.org/doi/10.1200/JC…

First-Line Nivolumab Plus Relatia Versus Nivolumab Plus Ipilimumab in Advanced #Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data brnw.ch/21wM27Z #melsm

In support of radiation dose escalation for non-small cell #lungcancer #radonc thelancet.com/journals/lanon…

Original Article: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) nej.md/4dUqm0g #ESMO24 | ESMO - Eur. Oncology

For early stage oropharyngeal cancer, definitive #radiotherapy has equivalent survival and PFS as TORS, with less pain and less dysphagia than surgery #radonc ascopubs.org/doi/abs/10.120…

Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: nej.md/4d0eZ5m

In the SPCG-4 randomized trial, conducted between 1989 and 2022 to compare radical prostatectomy with watchful waiting, radical prostatectomy led to a 48% lower risk of death from prostate cancer and to 2.2 life-years gained. Full trial results: nej.md/4eulajQ

Additional chemotherapy before standard treatment improves survival in women with a common form of cervical cancer, suggests study. Explore the findings ➡️ hubs.li/Q02Tpb2k0

PEACE-1 RT is now published online at The Lancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: thelancet.com/journals/lance…

Presented at #SABCS24: Interim results from the EUROPA trial: Single-modality #endocrinetherapy vs #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #breastcancer thelancet.com/journals/lanon…

Eliminating breast surgery for invasive breast cancer after neoadjuvent chemotherapy 👇🏼👇🏼👇🏼 No recurrence at 5 yr FU. ⁦Henry Kuerer⁩ #SSO2025 ⁦Society of Surgical Oncology⁩ ⁦MD Anderson Cancer Center⁩

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

📢 #ASCO25 | CAN-2409 + EBRT +/- ADT Ph. III | Localized Prostate Cancer: CAN-2409 + valacyclovir + EBRT +/- short-course ADT vs placebo n=745; 30% reduction in recurrence/death (DFS HR 0.70) with no added toxicity. Oral presentation by Dr. #TheodoreDeWeese from Johns Hopkins Medicine

.Journal of Clinical Oncology Phase III RCT FLAME (n=571). Focal boost (95 Gy) + standard EBRT (77 Gy) vs standard EBRT alone for localized intermediate-/high-risk prostate cancer showed improved 10-yr bDFS (86% vs 71%). PMID:40758955 pubmed.ncbi.nlm.nih.gov/40758955/

New today in #PracticalRO: Joint guideline from ASTRO, ASCO & SSO on post-mastectomy radiation therapy for patients with breast cancer. Updated recommendations cover indications, dosing, fractionation & multidisciplinary techniques. #RadOnc #BreastCancer ow.ly/524k50WXGao

"SBRT and surgery had similar 10-year outcomes, reinforcing the initial five-year data that we have previously presented from this trial," says Joe Y Chang of radiation for early-stage non-small cell lung cancer treatment. (1/2) #EndCancer

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

📢 JAMA Oncol (Oct 2, 2025): Phase 2 RCT: PSMA PET–guided intensification of salvage RT post-prostatectomy shows improved biochemical control vs standard RT. ➡️ Suggests molecular imaging can personalize salvage therapy. 👉10.1001/jamaoncol.2025.3625 JAMA Oncology ONCOassist® | The go-to oncology app

Presented at #ESMO25: In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival. Full EMBARK phase 3 trial

🌙LUNAR phase 2 RCT: adding Lu-177 PSMA to SABR for oligorecurrent prostate cancer significantly improved PFS without increased toxicity Just out in Journal of Clinical Oncology: ascopubs.org/doi/pdf/10.120… Impressive trial and results Amar Kishan Jeremie Calais and team